Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
by Zacks Equity Research
Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.
Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase
by Zacks Equity Research
Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated report on Endocyte, Inc. (ECYT) on May 17.
J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021
by Zacks Equity Research
Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.
The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status
by Zacks Equity Research
Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.
5 Reasons Why Merck (MRK) is a Good Stock to Buy Now
by Zacks Equity Research
It looks like a great stock to buy now.
Stock Market Today & Home Depot, Pfizer and ConocoPhillips Research Reports
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Home Depot (HD) and ConocoPhillips (COP).
Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study
by Arpita Dutt
While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.
Model N (MODN) Q2 Loss Narrower than Expected, Guides Well
by Zacks Equity Research
Model N, Inc. (MODN) reported second-quarter 2017 adjusted loss of 25 cents per share, which was wider than the year-ago quarter's loss of 21 cents.
Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit
by Arpita Dutt
Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.
Dow 30 Stock Roundup: Apple, Merck Beat; Pfizer Misses on Revenues
by Swarup Gupta
The Dow traded inside a tight band during a week marked by key earnings releases and legislative developments.
Merck vs. Pfizer: Which Stock Looks Better Post-Earnings?
by Zacks Equity Research
Pfizer is better positioned than Merck and thus calls for investors' attention post earnings.
Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) posted first-quarter 2017 loss of 76 cents per share (including stock-based compensation), wider than the Zacks Consensus Estimate of a loss of 74 cents.
Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Momenta Pharmaceuticals Inc. (MNTA) reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.
Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More
by Zacks Equity Research
Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.
Merck (MRK) Beats on Q1 Earnings & Sales, Ups Annual View
by Zacks Equity Research
Merck & Co., Inc. (MRK) reported first-quarter 2017 earnings of 88 cents per share, which beat the Zacks Consensus Estimate of 83 cents.
Pfizer and Apple In Focus
by Zacks Equity Research
Pfizer and Apple In Focus
On Pfizer and Apple: 2 Titanic Stocks Reporting Earnings Today
by Mark Vickery
Instead of another run-down of the high number of companies reporting today, I'd like to focus on one company having reported before the bell and one coming after the close: Pfizer (PFE) and Apple (AAPL).
Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact
by Zacks Equity Research
Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.
Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook